Biopharma Industry Slated As China Pillar Industry, But Key Domestic Support Missing
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Biopharmaceuticals will take a share in the Chinese central government's RMB 62.8 billion ($9.18 billion) investment plan to facilitate 11 key projects during 2009 to 2010. China's State Council passed a policy in May to promote the biotech industry to develop it as one of China's pillar industries in the future
You may also be interested in...
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
China Is Raising Government Support For Biotech Industry In Next Five-year Plan
SHANGHAI - While China's National Development and Reform Commission is drafting its 12th five-year plan, government officials and its think tank recently disclosed that the biotech industry will be raised as a pillar industry and China is increasing its support to facilitate development of the industry